Intralesional Immunotherapy of Melanoma with BCG
- 1 May 1976
- journal article
- Published by Elsevier BV in Medical Clinics of North America
- Vol. 60 (3), 419-430
- https://doi.org/10.1016/s0025-7125(16)31889-2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Differentiation between B cells, T cells, and histiocytes in melanocytic lesions: Primary and metastatic melanoma and halo and giant pigmented neviClinical Immunology and Immunopathology, 1975
- The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanomaCancer, 1975
- Immunoelectronmicroscopic Analysis of Surface Antigens Common to Mycobacterium bovis (BCG) and Tumor Cells2JNCI Journal of the National Cancer Institute, 1974
- Histopathology of Tumor Regression After Intralesional Injection of Mycobacferium bovis . IV. Development of Immunity to Tumor Cells and BCG 2JNCI Journal of the National Cancer Institute, 1973
- Immunopotentiation With BeG. I. Immune Response to Different Strains and Preparations2JNCI Journal of the National Cancer Institute, 1973
- Antigenic Relationship Between Mycobacterium bovis (BCG) and a Guinea Pig HepatomaJNCI Journal of the National Cancer Institute, 1973
- B.C.G. IN MALIGNANT MELANOMAThe Lancet, 1973
- Serum‐mediated blocking of cell‐mediated anti‐tumor immunity in a melanoma patient: Association with BCG immunotherapy and clinical deteriorationInternational Journal of Cancer, 1972
- Local tumor immunotherapy with in vitro activated autochthonous lymphocytesCancer, 1972
- Use of Vaccinia Virus in the Treatment of Metastatic Malignant MelanomaBMJ, 1970